TQQQ vs XBI
ProShares UltraPro QQQ vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.82% for TQQQ.
- • TQQQ pays a higher dividend yield (0.50%).
Side-by-side metrics
| Metric | TQQQ | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.82% | 0.35% |
Dividend yield Trailing 12-month yield. | 0.50% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $31.34B | $8.30B |
YTD return | 35.97% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 3.75 | 1.09 |
P/E ratio | 36.57 | — |
Last price | $71.34 | $133.66 |
Inception | — | — |
Issuer | ProShares | State Street |
TQQQ top holdings
| IQMM | ProShares GENIUS Money Market ETF | 26.61% |
| NVDA | NVIDIA Corp | 3.49% |
| AAPL | Apple Inc | 2.87% |
| MSFT | Microsoft Corp | 2.18% |
| AMZN | Amazon.com Inc | 2.05% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About TQQQ
TQQQ (ProShares UltraPro QQQ) is 3x leveraged daily performance of the Nasdaq-100. Managed by ProShares, the fund carries $31.3B in assets under management, an expense ratio of 0.82%, a dividend yield of 0.50%. Its largest holding is ProShares GENIUS Money Market ETF (IQMM), which represents 26.6% of the portfolio. Real Estate is the fund's largest sector exposure at 0.1%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.